Am J Transplant, Volume 5, Suppl 3 Archives - Page 10 of 170 - ATC Abstracts

2015 American Transplant Congress
No Tumor Recurrence After Renal Cell Carcinoma Resected Kidney Transplantation – 5 Year Follow Up
M. Zwierzchoniewska,¹ K. Fong,¹ D. Patel,¹ L. Mou, W. Lim,² B. He,¹ L. Delriviere.¹
¹Western Australian Kidney Transplant Surgery Service, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia; ²Western Australian Kidney Transplant Service, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
INTRODUCTION:Organ shortage remains the single most significant impediment to increasing low rate of kidney transplantation. One of the strategies to improve it, is a utilisation…
2015 American Transplant Congress
Calcineurin (CNI) Exposure Reduces the Risk of Post-Transplant DSA After Deceased Donor Kidney Transplantation
R. Pelletier, A. Rajab, G. Bumgardner, M. Henry.
General Surgery, The Ohio State University, Columbus, OH.
We use ATG induction with immediate rapamune (Rapa) and delayed CNI immunosuppression following kidney transplantation. Mycophenolic acid (MPA) is substituted for CNI to avoid renal…
2015 American Transplant Congress
Interleukin-17 Deficiency Attenuates Renal Allograft Injury and Prolongs Survival in a Murine Transplantation Model
T. Kwan,^1,2 S. Chadban,^1,2 J. Ma,^1,2 S. Bao,^2,3 S. Alexander,^2,4 H. Wu.^1,2
¹Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia; ²Renal Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia; ³Discipline of Pathology, School of Medical Sciences, Sydney, New South Wales, Australia; ⁴Centre for Kidney Research, The Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Aim:To investigate the role of IL-17 in allograft rejection using a murine model of fully MHC-mismatched renal transplantation.Methods:Life-sustaining kidney transplants were performed in nephrectomized mice:…
2015 American Transplant Congress
The Effects of Periostin on Renal Fibrosis After Ischemia-Reperfusion Injury Via p38 MAPK Pathway
J. An,^1,2 S. Yang,³ J. Hwang,⁴ J. Kim,¹ S. Kim,^2,5 C. Lim,^1,2 Y. Oh,^1,2 Y. Kim,² J. Lee.^1,2
¹Seoul National University Boramae Medical Center, Seoul, Republic of Korea; ²Seoul National University Hospital, Seoul, Republic of Korea; ³Seoul National University Kidney Research Institute, Seoul, Republic of Korea; ⁴Chung-Ang University Hospital, Seoul, Republic of Korea; ⁵Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
Ischemia-reperfusion injury during the transplantation procedure is associated with poor long-term allograft outcomes, such as rejection and fibrosis. Periostin, a matricellular protein, has been reported…
2015 American Transplant Congress
Type III Phosphodiesterase (PDE3) Inhibitor Improves Survival Rate After Ischemia Reperfusion Injury of the Liver in Rats
T. Fujii,¹ H. Obara,² N. Fujimura,² K. Matsubara,² Y. Kitagawa.²
¹Surgery, Inagi Municipal Hospital, Tokyo, Japan; ²Surgery, Keio University School of Medicine, Tokyo, Japan.
BackgroundPDE3 inhibitor (Cilostazol) has long been used as a potent inhibitor of platelet aggregation and thrombosis. Recently, there have been a report on the protective…
2015 American Transplant Congress
Influence of CYP3A5 and ABCB1 Genotypes on Pharmacokinetics of Immediate and Prolonged Release Tacrolimus Preparations
T. Elnahhas,^1,2 T. Lee,² M. Moreton,² D. McKeown,² J. Popoola,³ R. Ramkhelawon,³ A. Johnston,^1,2 I. MacPhee.³
¹Clinical Pharmacology Department, Queen Mary University of London, London, United Kingdom; ²Analytical Services International, St.George's University of London, London, United Kingdom; ³Institute of Medical and Biomedical Education-Renal Medicine, St.George's University of London, London, United Kingdom.
Background. Tacrolimus is available in two formulations, immediate-release, (Prograf®) and prolonged -release formulation of tacrolimus (Advagraf®). Tacrolimus has a narrow therapeutic index with wide variation…
2015 American Transplant Congress
Calcineurin Inhibitors (CNI) Minimization Associated With Mammalian Target of Rapamycin Inhibitors (i-mTOR) to Improve Renal Function in Renal Grafts from Uncontrolled Donation After Cardiac Death Donors (UDCDD)
M. Molina,¹ E. Gutierrez,¹ S. González-Sanchidrian,² E. González,¹ J. Cabrera,¹ N. Polanco,¹ A. Hernández,¹ A. Sevillano,¹ M. Praga,¹ A. Andres.¹
¹Nephrology, Hospital 12 de Octubre, Madrid, Spain; ²Nephrology, Hospital San Pedro de Alcántara, Caceres, Spain.
INTRODUCTION: Ischemia injury in kidneys grafts from UDCDD could produce a poor renal function. Minimized blood levels of CNI associated with i-mTOR therapy could avoid…
2015 American Transplant Congress
Significance of an Isolated Elevated PRA in Renal Transplantation
S. Kuten, S. Patel, G. Land, T. Eagar, R. Knight, J. Loucks, L. Gaber, A. Gaber.
Houston Methodist Hospital, Houston, TX.
Transplant centers have traditionally discerned a patient's immunologic risk based on peak panel reactive antibody (PRA) levels. However, in a given patient, pre-transplant PRA may…
2015 American Transplant Congress
Alpha-Fetoprotein as a Modifier of Anatomic Criteria for Transplantation of HCC Patients
A. Daoud,^1,3 M. Ghobrial,¹ L. Teeter,² E. Graviss,² E. Asham,¹ S. Burroughs,¹ A. Saharia,¹ C. Mobley,¹ S. Mogawer,³ A. Sholkamy,³ M. Elshazly,⁴ M. Boktour,¹ A. Gaber.¹
¹Transplant Center, Methodist Hospital, Houston, TX; ²Pathology and Genomic Medicine, Methodist Hospital, Houston, TX; ³Internal Medicine Department, Cairo University Medical school, Cairo, Egypt; ⁴Surgery Department, Cairo University Medical school, Cairo, Egypt.
Background:The current listing criteria (Milan, UCSF) for Orthotropic Liver Transplants (OLT) in hepatocellular carcinoma (HCC) patients emphasize the anatomic features of the tumor such as…
2015 American Transplant Congress
Clinical Impact of 18F-FDG-PET/CT in Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma
S. Lee, S. Kim.
Liver Cancer Center, National Cancer Center, Goyang, Korea.
Background: The relevant number of patients with hepatocellular carcinoma (HCC) beyond the Milan criteria has undergone living donor liver transplantation (LDLT). However, the prognostic factors…